ELVN NASDAQ
Enliven Therapeutics, Inc.
1W: -1.9%
1M: -4.9%
3M: +62.4%
YTD: +171.9%
1Y: +143.1%
3Y: +113.2%
5Y: +31.2%
$41.54
-0.71 (-1.68%)
Weekly Expected Move ±6.0%
$36
$39
$41
$44
$46
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q1 2026183
Institutions Holding
+30 vs prior
75.4%
Ownership
+37.45%
56
New
57
Increased
58
Reduced
33
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-17 | Collins Helen Louise | officer: chief medical officer | S-Sale | 2,441 | $48.06 | $117K | Filing |
| 2026-04-17 | Collins Helen Louise | officer: chief medical officer | S-Sale | 2,419 | $47.39 | $115K | Filing |
| 2026-04-17 | Collins Helen Louise | officer: chief medical officer | S-Sale | 140 | $45.81 | $6K | Filing |
| 2026-03-25 | Collins Helen Louise | officer: chief medical officer | S-Sale | 40,000 | $35.10 | $1.4M | Filing |
| 2026-03-17 | Collins Helen Louise | officer: chief medical officer | S-Sale | 5,000 | $27.76 | $139K | Filing |
| 2026-02-17 | Collins Helen Louise | officer: chief medical officer | S-Sale | 45,000 | $26.17 | $1.2M | Filing |
| 2026-02-17 | Heyman Richard A. | director | S-Sale | 1,230 | $26.18 | $32K | Filing |
| 2026-02-12 | Collins Helen Louise | officer: chief medical officer | A-Grant/Award | 25,000 | $— | $0 | Filing |
| 2026-02-12 | Hohl Benjamin | officer: chief financial officer | A-Grant/Award | 25,000 | $— | $0 | Filing |
| 2026-02-12 | Lyssikatos Joseph P | officer: chief scientific officer | A-Grant/Award | 18,750 | $— | $0 | Filing |
| 2026-02-12 | Patel Anish | officer: chief operating officer | A-Grant/Award | 20,000 | $— | $0 | Filing |
| 2026-02-06 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 5,000 | $29.04 | $145K | Filing |
| 2026-01-20 | Heyman Richard A. | director | S-Sale | 512 | $26.46 | $14K | Filing |
| 2026-01-20 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 5,491 | $26.37 | $145K | Filing |
| 2026-01-20 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 14,509 | $26.90 | $390K | Filing |
| 2026-01-20 | Heyman Richard A. | director | S-Sale | 718 | $26.96 | $19K | Filing |
| 2026-01-09 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 41,198 | $24.90 | $1.0M | Filing |
| 2026-01-09 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 50,000 | $29.13 | $1.5M | Filing |
| 2026-01-09 | Patel Anish | officer: chief operating officer | S-Sale | 48,057 | $27.98 | $1.3M | Filing |
| 2026-01-09 | Patel Anish | officer: chief operating officer | S-Sale | 243 | $28.50 | $7K | Filing |
| 2026-01-09 | Heyman Richard A. | director | S-Sale | 4,285 | $25.00 | $107K | Filing |
| 2026-01-08 | Heyman Richard A. | director | S-Sale | 8,015 | $25.04 | $201K | Filing |
| 2026-01-08 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 33,802 | $24.92 | $842K | Filing |
| 2026-01-08 | Lyssikatos Joseph P | officer: chief scientific officer | S-Sale | 7,500 | $20.13 | $151K | Filing |
| 2026-01-08 | Heyman Richard A. | director | S-Sale | 1,620 | $25.00 | $40K | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7,959,538 | $312M | — | 2026-03-31 | Filing |
| FMR LLC | 6,829,246 | $268M | -278,389 | 2026-03-31 | Filing |
| Polar Capital Holdings Plc | 5,065,933 | $199M | +1,552,253 | 2026-03-31 | Filing |
| BlackRock, Inc. | 3,684,707 | $144M | +71,381 | 2026-03-31 | Filing |
| Commodore Capital LP | 3,275,000 | $128M | -1,417,809 | 2026-03-31 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,168,162 | $85M | +2,168,162 | 2026-03-31 | Filing |
| Fairmount Funds Management LLC | 1,855,644 | $73M | -1,855,800 | 2026-03-31 | Filing |
| STATE STREET CORP | 1,091,106 | $43M | +38,244 | 2026-03-31 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 1,066,420 | $42M | +17,698 | 2026-03-31 | Filing |
| Pictet Asset Management Holding SA | 929,544 | $36M | -373,691 | 2026-03-31 | Filing |
| Rock Springs Capital Management LP | 826,500 | $32M | +28,095 | 2026-03-31 | Filing |
| Siren, L.L.C. | 746,226 | $29M | +746,226 | 2026-03-31 | Filing |
| DIMENSIONAL FUND ADVISORS LP | 681,715 | $27M | +282,822 | 2026-03-31 | Filing |
| First Turn Management, LLC | 623,839 | $24M | +623,839 | 2026-03-31 | Filing |
| Candriam S.C.A. | 594,079 | $23M | +141,060 | 2026-03-31 | Filing |
| Jones Hill Capital LP | 593,040 | $23M | +593,040 | 2026-03-31 | Filing |
| Affinity Asset Advisors, LLC | 586,904 | $23M | +586,904 | 2026-03-31 | Filing |
| Logos Global Management LP | 540,000 | $21M | +200,000 | 2026-03-31 | Filing |
| GOLDMAN SACHS GROUP INC | 473,115 | $19M | +235,911 | 2026-03-31 | Filing |
| Avidity Partners Management LP | 400,000 | $16M | +259,700 | 2026-03-31 | Filing |